NRAS and cutaneous melanoma: Unlike the previous reports indicating shorter survival for NRAS mutant non‐cutaneous melanoma patients receiving ICIs compared to NRAS wild‐type patients,29 our analysis showed similar PFS between NRAS mutant and NRAS wild‐type patients (median: 13.3 months, 95% CI, 1.2–not reached vs. 9.8 months, 95% CI, 5.5–14.2; HR = 1.65, 95% CI, .69–3.99; p = .272; Figure 3A).